Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target?
Abstract Osteosarcoma is the most common primary malignant bone tumour in children and adolescents. More than a third of patients do not respond to standard therapy and urgently require alternative treatment options. Due to a high degree of inter‐ and intra‐tumoural genomic heterogeneity and complex...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-03-01
|
| Series: | The Journal of Pathology: Clinical Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cjp2.191 |
| _version_ | 1818457595124383744 |
|---|---|
| author | Baptiste Ameline Michal Kovac Michaela Nathrath Maxim Barenboim Olaf Witt Andreas H Krieg Daniel Baumhoer |
| author_facet | Baptiste Ameline Michal Kovac Michaela Nathrath Maxim Barenboim Olaf Witt Andreas H Krieg Daniel Baumhoer |
| author_sort | Baptiste Ameline |
| collection | DOAJ |
| description | Abstract Osteosarcoma is the most common primary malignant bone tumour in children and adolescents. More than a third of patients do not respond to standard therapy and urgently require alternative treatment options. Due to a high degree of inter‐ and intra‐tumoural genomic heterogeneity and complexity, recurrent molecular alterations that could serve as prognostic predictors or therapeutic targets are still lacking in osteosarcoma. Copy number (CN) gains involving the IGF1R gene, however, have been suggested as a potential surrogate marker for treating a subset of patients with IGF1R inhibitors. In this study, we screened a large set of osteosarcomas and found specific CN gains of the IGF1R gene in 18 of 253 (7.1%) cases with corresponding IGF1R overexpression. Despite the discouraging results observed in clinical trials in other tumours so far, focusing only on selected patients with osteosarcoma that show evidence of IGF pathway activation might represent a promising new and innovative treatment approach. |
| first_indexed | 2024-12-14T22:45:03Z |
| format | Article |
| id | doaj.art-5800e7b1df6641a3904e905f4099abd3 |
| institution | Directory Open Access Journal |
| issn | 2056-4538 |
| language | English |
| last_indexed | 2024-12-14T22:45:03Z |
| publishDate | 2021-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Journal of Pathology: Clinical Research |
| spelling | doaj.art-5800e7b1df6641a3904e905f4099abd32022-12-21T22:44:52ZengWileyThe Journal of Pathology: Clinical Research2056-45382021-03-017216517210.1002/cjp2.191Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target?Baptiste Ameline0Michal Kovac1Michaela Nathrath2Maxim Barenboim3Olaf Witt4Andreas H Krieg5Daniel Baumhoer6Bone Tumour Reference Centre at the Institute of Pathology University Hospital Basel, University of Basel Basel SwitzerlandBone Tumour Reference Centre at the Institute of Pathology University Hospital Basel, University of Basel Basel SwitzerlandDepartment of Pediatrics and Children's Cancer Research Center, Klinikum rechts der Isar Technical University of Munich, School of Medicine Munich GermanyDepartment of Pediatrics and Children's Cancer Research Center, Klinikum rechts der Isar Technical University of Munich, School of Medicine Munich GermanyCoordinator INFORM Program, Hopp Children's Cancer Center, German Cancer Research Center University Hospital Heidelberg Heidelberg GermanyBone and Soft tissue Sarcoma Center University of Basel, University Childrens Hospital (UKBB) Basel SwitzerlandBone Tumour Reference Centre at the Institute of Pathology University Hospital Basel, University of Basel Basel SwitzerlandAbstract Osteosarcoma is the most common primary malignant bone tumour in children and adolescents. More than a third of patients do not respond to standard therapy and urgently require alternative treatment options. Due to a high degree of inter‐ and intra‐tumoural genomic heterogeneity and complexity, recurrent molecular alterations that could serve as prognostic predictors or therapeutic targets are still lacking in osteosarcoma. Copy number (CN) gains involving the IGF1R gene, however, have been suggested as a potential surrogate marker for treating a subset of patients with IGF1R inhibitors. In this study, we screened a large set of osteosarcomas and found specific CN gains of the IGF1R gene in 18 of 253 (7.1%) cases with corresponding IGF1R overexpression. Despite the discouraging results observed in clinical trials in other tumours so far, focusing only on selected patients with osteosarcoma that show evidence of IGF pathway activation might represent a promising new and innovative treatment approach.https://doi.org/10.1002/cjp2.191osteosarcomaIGF1Rtargeted treatmentchromoanagenesis |
| spellingShingle | Baptiste Ameline Michal Kovac Michaela Nathrath Maxim Barenboim Olaf Witt Andreas H Krieg Daniel Baumhoer Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target? The Journal of Pathology: Clinical Research osteosarcoma IGF1R targeted treatment chromoanagenesis |
| title | Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target? |
| title_full | Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target? |
| title_fullStr | Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target? |
| title_full_unstemmed | Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target? |
| title_short | Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target? |
| title_sort | overactivation of the igf signalling pathway in osteosarcoma a potential therapeutic target |
| topic | osteosarcoma IGF1R targeted treatment chromoanagenesis |
| url | https://doi.org/10.1002/cjp2.191 |
| work_keys_str_mv | AT baptisteameline overactivationoftheigfsignallingpathwayinosteosarcomaapotentialtherapeutictarget AT michalkovac overactivationoftheigfsignallingpathwayinosteosarcomaapotentialtherapeutictarget AT michaelanathrath overactivationoftheigfsignallingpathwayinosteosarcomaapotentialtherapeutictarget AT maximbarenboim overactivationoftheigfsignallingpathwayinosteosarcomaapotentialtherapeutictarget AT olafwitt overactivationoftheigfsignallingpathwayinosteosarcomaapotentialtherapeutictarget AT andreashkrieg overactivationoftheigfsignallingpathwayinosteosarcomaapotentialtherapeutictarget AT danielbaumhoer overactivationoftheigfsignallingpathwayinosteosarcomaapotentialtherapeutictarget |